Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ana-Maria Vranceanu, Ph.D.

Co-Author

This page shows the publications co-authored by Ana-Maria Vranceanu and Scott Plotkin.
Connection Strength

4.631
  1. Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial. JMIR Res Protoc. 2018 Oct 23; 7(10):e11008.
    View in: PubMed
    Score: 0.818
  2. Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT. Neurology. 2016 Aug 23; 87(8):806-14.
    View in: PubMed
    Score: 0.700
  3. Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol. 2015 Apr; 122(2):219-28.
    View in: PubMed
    Score: 0.633
  4. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013 Sep; 114(3):257-62.
    View in: PubMed
    Score: 0.566
  5. Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program. J Neurooncol. 2020 Apr; 147(2):451-457.
    View in: PubMed
    Score: 0.224
  6. Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial. Gen Hosp Psychiatry. 2020 Jan - Feb; 62:72-78.
    View in: PubMed
    Score: 0.221
  7. Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live-video randomized control trial. J Neurooncol. 2019 Dec; 145(3):561-569.
    View in: PubMed
    Score: 0.220
  8. First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial. J Neurooncol. 2019 Jul; 143(3):505-513.
    View in: PubMed
    Score: 0.212
  9. Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT. J Neurooncol. 2018 Jan; 136(2):335-342.
    View in: PubMed
    Score: 0.191
  10. First report of factors associated with satisfaction in patients with neurofibromatosis. . 2017 03; 173(3):671-677.
    View in: PubMed
    Score: 0.183
  11. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. J Neurooncol. 2017 01; 131(2):413-419.
    View in: PubMed
    Score: 0.179
  12. Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History Study. Otol Neurotol. 2016 06; 37(5):574-9.
    View in: PubMed
    Score: 0.173
  13. Examining perceived cancer risk among patients with neurofibromatosis type 1. J Neurooncol. 2015 Mar; 122(1):127-33.
    View in: PubMed
    Score: 0.157
  14. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. J Neurooncol. 2014 Oct; 120(1):103-9.
    View in: PubMed
    Score: 0.152
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.